TOKYO, January 23, 2023 /PRNewswire/ — ThinkCyte, a biotech company pioneering a novel artificial intelligence (AI)-based cell isolation, characterization and analysis platform, today announced the appointments of Dr. Diether Recktenwald Ph. .D. and Dr. Bo EH Saxberg MD., Ph.D. to its senior Scientific Advisory Board (SAB). The appointments complement the strengths of ThinkCyte’s existing advisory team and bring to ThinkCyte’s SAB deep knowledge of experience in emerging flow cytometry markets, strategic product development and clinical applications.

Dr. Recktenwald has a long career in the development of flow cytometry instruments. He spent more than three decades at Becton Dickinson (BD) Biosciences, culminating as Vice President of Advanced Technologies, where he guided the advanced development of several new flow cytometry technologies and product lines. Previously, he was Director of Industrial and Environmental Biosciences at BD, where he was responsible for evaluating and developing novel flow cytometry detection methods for emerging markets. Earlier in his career as Vice President R&D for BD Biosciences Immunocytometry Systems, he led the development of several new flow cytometry systems, consumables and accessory lines. He holds a bachelor’s and master’s degree in chemistry from the University of Saarland, obtained a doctorate. in biology from the Ruhr-University Bochum in Germanyand carried out postdoctoral research in cell biology and biophysics at Stanford University.

“I was honored to join the ThinkCyte Advisory Board to contribute to the approach and vision of their great team,” said Dr. Recktenwald. “By combining the fluorescence detection capabilities of traditional flow cytometry with a new way to obtain morphological details and data on single cells and by applying AI, this opens up new applications in life science research. life and beyond. I look forward to working with the extremely accomplished team as an advisory board member to help realize this vision.”

Dr. Saxberg has a distinguished career spanning the pharmaceutical, academic and government research sectors, helping to drive innovations in pharmaceutical and diagnostic therapies and related development technologies, including serving as a founding investor and later Chairman of the Board of administration of IntelliCyt, a pioneer in the field of high-throughput flow cytometry. Previously, he served as Vice President, Corporate Staff, Advanced Communications at Johnson & Johnson and Vice President, New Business Development and Advanced Communications for eJNJ, LLC, a subsidiary of Johnson & Johnson founded in 2000 to focus on opportunities for digital e-health. Previously, he was at Eli Lilly as Director of Information Science leading projects at the interface of new technologies and pharmaceutical industry innovation. Dr. Saxberg graduated summa cum laude from the University of Washington, where he obtained an honors bachelor’s degree in mathematics and an honors bachelor’s degree in chemistry. Dr. Saxberg also obtained an Honors BA/MA Cantab. in physics of Cambridge University in Englandan MD of Harvard University, and a Ph.D. in physics of Massachusetts Institute of Technology.

“ThinkCyte’s unique morphology-based approach to single cell analysis and sorting is a fundamental advancement in the field and one of the main reasons I’m so excited to join the advisory board. said Dr. Saxberg. “By combining a truly new way to examine cells with the power of AI to uncover hidden patterns in data, ThinkCyte offers a whole new way to see the relationship between cellular phenotypes and disease.”

“We are delighted to have Drs Recktenwald and Saxberg join our SAB alongside a team of renowned interdisciplinary experts in technology and science,” said Janette Phi, Chief Commercial Officer at ThinkCyte. “Their experience in identifying areas where new cytometry technologies can bring value to the biomedical research and healthcare markets complements the strengths of our current advisory board and will position us well to advance the ThinkCyte’s vision to bring a new dimension in cellular analysis to the world.

About ThinkCyte Inc.

ThinkCyte, founded in 2016 with offices in Tokyo, Japan and San Carlos, California. is a biotechnology company that develops innovative scientific instruments based on integrated and multidisciplinary technologies to enable research, diagnosis and therapeutic development in the life sciences. The company launched Ghost Cytometry, a proprietary AI-based label-free cell sorting technology, and has partnered with leading global biopharmaceutical companies and leading academic research institutes to further drive pioneering research. For more information, visit

To learn more about research collaborations or other partnership opportunities with ThinkCyte, email [email protected].

Media Contact:
William Westerdoctorate
[email protected]

SOURCE ThinkCyte Inc.

Source link

Leave A Reply